drug · antibody
zalifrelimab
Phase 2updated 3mo agoby $AGEN AGENUS INC🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 4 investigational indications.
targets
Cytotoxic T-lymphocyte protein 4
all catalysts(0)
nothing on the calendar yet
Trials studying zalifrelimab
- phase2A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)
- phase2Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas
- —Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
- phase2AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
- phase2A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
- phase2Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
- phase2A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that